A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single- center experience
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The widespread use of cytotoxic chemotherapy and immunosuppressants has resulted in reactivation of hepatitis B virus (HBV) recently becoming an issue. Although rituximab (an anti-CD20 monoclonal antibody) has revolutionized the treatment of lymphoma, recent reports have suggested that rituximab therapy increases the risk of viral-mediated complications, and particularly HBV reactivation. This study analyzed real clinical practice data for rituximab-related HBV reactivation. Methods: Between January 2005 and December 2011, 169 patients received treatment with rituximab. Screening status of the HBV infection and frequency of preemptive therapy were determined in these patients, and the clinical features of HBV reactivation were analyzed. Results: Seventy-nine of the 169 patients with chronic or past HBV infection were selected for evaluation of HBV reactivation. Of the 90 patients who were excluded, 22 (13.0%) were not assessed for HBsAg and anti-HBc, and 14 (8.3%)were not assessed for anti-HBc due to seronegativity for HBsAg. The selected patients were divided into those with chronic HBV infection (n=12) and those with past HBV infection (n=67); six patients (7.6%) experienced HBV reactivation. Eight patients received preemptive therapy, but three patients (37.5%) underwent HBV reactivation. Although HBsAg seropositivity was an independent risk factor for HBV reactivation (P=0.038), of the six patients with HBV reactivation,two (33.3%) had past HBV infection and three (50%) died of liver failure. Conclusions: The findings of this study demonstrate that adherence to guidelines for screening and preemptive therapy for HBV reactivation was negligent among the included cohort. Attention should be paid to HBV reactivation in patients with past as well as chronic HBV infection during and after rituximab therapy. (Clin Mol Hepatol 2013;19:51-59)
Abstract
Background/Aims: The widespread use of cytotoxic chemotherapy and immunosuppressants has resulted in reactivation of hepatitis B virus (HBV) recently becoming an issue. Although rituximab (an anti-CD20 monoclonal antibody) has revolutionized the treatment of lymphoma, recent reports have suggested that rituximab therapy increases the risk of viral-mediated complications, and particularly HBV reactivation. This study analyzed real clinical practice data for rituximab-related HBV reactivation. Methods: Between January 2005 and December 2011, 169 patients received treatment with rituximab. Screening status of the HBV infection and frequency of preemptive therapy were determined in these patients, and the clinical features of HBV reactivation were analyzed. Results: Seventy-nine of the 169 patients with chronic or past HBV infection were selected for evaluation of HBV reactivation. Of the 90 patients who were excluded, 22 (13.0%) were not assessed for HBsAg and anti-HBc, and 14 (8.3%)were not assessed for anti-HBc due to seronegativity for HBsAg. The selected patients were divided into those with chronic HBV infection (n=12) and those with past HBV infection (n=67); six patients (7.6%) experienced HBV reactivation. Eight patients received preemptive therapy, but three patients (37.5%) underwent HBV reactivation. Although HBsAg seropositivity was an independent risk factor for HBV reactivation (P=0.038), of the six patients with HBV reactivation,two (33.3%) had past HBV infection and three (50%) died of liver failure. Conclusions: The findings of this study demonstrate that adherence to guidelines for screening and preemptive therapy for HBV reactivation was negligent among the included cohort. Attention should be paid to HBV reactivation in patients with past as well as chronic HBV infection during and after rituximab therapy. (Clin Mol Hepatol 2013;19:51-59)
참고문헌 (27)
- Lai CL, "Chronic hepatitis B--new goals, new treatment", N Engl J Med, 359, pp.2488~2491 (2008)
- Lim SH, "Anti-CD20 monoclonal antibodies: historical and future perspectives", Haematologica, 95, pp.135~143 (2010)
- Gürcan HM, "A review of the current use of rituximab in autoimmune diseases", Int Immunopharmacol, 9, pp.10~25 (2009)
- Yeo W, "Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy", Hepatology, 43, pp.209~220 (2006)
- Watanabe M, "Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection", Liver Int, 31, pp.340~347 (2011)
- Lee WM, "Hepatitis B virus infection", N Engl J Med, 337, pp.1733~1745 (1997)
- Liang R, "How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation", Blood, 113, pp.3147~3153 (2009)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- European Association For The Study Of The Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Hui CK, "Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy", Gastroenterology, 131, pp.59~68 (2006)
- Yeo W, "Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab", J Clin Oncol, 27, pp.605~611 (2009)
- Katz LH, "Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis", J Viral Hepat, 15, pp.89~102 (2008)
- Loomba R, "Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy", Ann Intern Med, 148, pp.519~528 (2008)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update", Hepatol Int, 2, pp.263~283 (2008)
- Yeo W, "Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy", J Med Virol, 59, pp.263~269 (1999)
- Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy", Gastroenterology, 125, pp.1742~1749 (2003)
- Lok AS, "Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study", Gastroenterology, 100, pp.182~188 (1991)
- Markovic S, "Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients", Hepatogastroenterology, 46, pp.2925~2930 (1999)
- Lim LL, "Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients", Aliment Pharmacol Ther, 16, pp.1939~1944 (2002)
- Aksoy S, "Rituximab-related viral infections in lymphoma patients", Leuk Lymphoma, 48, pp.1307~1312 (2007)
- Liang R, "Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem", J Clin Oncol, 17, pp.394~398 (1999)
- Sanchez MJ, "Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab", J Hepatol, 51, pp.1091~1096 (2009)
- Dillon R, "Fatal reactivation of hepatitis B after chemotherapy for lymphoma", BMJ, 337, pp.a423~ (2008)
- Law JK, "Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibodypositive patient: potential implications for future prophylaxis recommendations", Leuk Lymphoma, 46, pp.1085~1089 (2005)
- Hui CK, "Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy", Blood, 105, pp.2616~2617 (2005)
- Calabrese LH, "Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies", Ann Rheum Dis, 65, pp.983~989 (2006)
- Suzuki H, "Mutations of glucocorticoid responsive element of HBV DNA", Kurume Med J, 45, pp.171~174 (1998)